Predictive Oncology a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncologic drug discovery and enable drug development, issued the following letter to shareholders:
Dear Shareholders and Stakeholders,
As all of you know, on November 1, 2022, I had the privilege of being asked to serve as Chief Executive Officer of Predictive Oncology Inc. It is a responsibility that I take very seriously, and a commitment that I made without the slightest reservation. Predictive Oncology is a company that I believe in, with a mission that is achievable, and a vision that is honorable. That mission is to expedite oncologic drug discovery, enable drug development and that vision is to bring hope to cancer patients waiting for therapies that might improve or extend their lives faster than currently thought possible.
Recommended AI News: Wirelesscar Announces AI-Research Project for Sustainable Mobility
As you also know, we began this journey under less-than-optimal circumstances: management was in transition, milestones had been delayed, the stock price had dipped below $0.24, and the company was deficient. While disheartening, to be sure, the Company has managed to weather the deleterious effect of intensely volatile capital markets and the still-lingering impact of a global pandemic. We have not only survived these external pressures, but have made significant progress with respect to validating our commercial platform and publishing our proof of concept.
As frustrating as this process has been, however, the Company is now able to focus all of its energy and resources on conducting transactions with biopharmaceutical partners and driving adoption of our proprietary PEDAL platform. While we believe that PEDAL is the drug discovery engine that will ultimately drive the future growth of the Company, it is the synergy and interoperability of PEDAL, in concert with the Company’s foundational assets of a CLIA laboratory, biorepository of tumor samples and GMP facility that will transform our business. At the center of these developments and activities is a highly specialized team of world class scientists whose collective intellectual capital is invaluable.
Recommended AI News: Transport Tech Scaleup Vivacity Labs Partners With Monmouthshire County Council to Promote Safe Cycling in Abergavenny
Lastly, it is important for me to say that, even during the silence that has permeated this difficult transition, one must appreciate the fact that all of the progress that has been made during the past few months has only been possible because of the significant and sustained investment in this Company. While it may not be immediately obvious, I believe that the results of this investment will become self-evident. While we may have been slowed by circumstance, we have never given up on the Company, the shareholders nor ourselves. I believe that Predictive Oncology will ultimately succeed, not only because of the ongoing support of our shareholders, stakeholders and customers, but because of the unflinching commitment of our Board of Directors, Senior Management and the entire team of professionals at Predictive Oncology.
Recommended AI News: Transport Tech Scaleup Vivacity Labs Partners With Monmouthshire County Council to Promote Safe Cycling in Abergavenny
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.